Erytech Pharma Inc.
One Main Street
123 articles with Erytech Pharma Inc.
French biopharmaceutical company aims to improve data access, quality, and workflow efficiencies
ERYTECH Pharma announced that it will present preclinical data on the enzymatic activity of eryaspase (GRASPA®) at the European Hematology Association (EHA) Congress
Lyonbiopole the French "bio-cluster" based in the Auvergne-Rhône-Alpes region, will unite 35 innovative organizations at the 2018 edition of the BIO International Convention.
Following these very encouraging results, ERYTECH conducted a comprehensive evaluation to determine other potential solid-tumor indications for developing eryaspase.
The study enrolled a total of 123 patients at 30 European sites.
Announced full exercise of underwriters’ option to purchase additional American Depositary Shares (ADSs) and Ordinary Shares, with closing expected to take place on or about November 16, 2017.
ERYTECH announced that it will host a Third Quarter 2017 conference call and webcast on Tuesday, November 14, 2017, at 2:30 PM CET/8:30 AM EST to discuss operational highlights.
Net loss for the nine-month period ended September 30, 2017 was €20.8 million, compared to €16.1 million for the same period in the prior year.
ERYtech Pharma Announces Resubmission Of European Marketing Authorization Application For GRASPA In Acute Lymphoblastic Leukemia
ERYtech Pharma Reports Determination Of The Recommended Pivotal Phase 3 Dose Of Eryaspase In Its U.S. Phase 1 Study In First Line Adult ALL
ERYtech Pharma Announces Positive Full Results From Phase IIb Study Of Eryaspase In Combination With Chemotherapy For Treatment Of Metastatic Pancreatic Cancer In Second-Line
ERYtech Pharma To Present Pre-Clinical Data At The 13th International Congress Of Inborn Errors Of Metabolism
ERYtech Pharma To Present Full Results For Phase IIb Trial Of Eryaspase In Pancreatic Cancer At ESMO 2017
ERYtech Pharma Announces Collaboration With Queen’s University To Advance Its Product Candidate For Rare Metabolic Disorders
ERYtech Pharma Announces Launch Of Investigator-Initiated Phase II Study Of Eryaspase (GRASPA) For ALL
ERYtech Pharma Reports Positive Phase IIb Data For Eryaspase For The Treatment Of Metastatic Pancreatic Cancer